局限性前列腺癌患者报告结局评估的标准化:一项系统综述
该系统综述评估了用于局限性前列腺癌的PROM测量学特性,共纳入27项研究,涵盖EPIC、UCLA-PCI、EORTC QLQ-C30、QLQ-PR25、IIEF、SF-36和SF-12。结论认为EORTC QLQ-C30和QLQ-PR25在常规实践和研究中的测量学证据和可行性最佳,且QLQ-C30需与QLQ-PR25联合使用。
要点
- EORTC QLQ-C30和QLQ-PR25在局限性前列腺癌PROM评估中测量学特性和可行性证据最佳。
- QLQ-C30为通用模块,不直接评估前列腺癌特异问题,应与QLQ-PR25联合使用。
- EPIC和EORTC QLQ-C30内部一致性高但内容效度低;UCLA-PCI不直接评估激素症状。
核心结论
- 在常规实践和研究中评估局限性前列腺癌患者PROM时,测量学特性证据和可行性最佳的工具是EORTC QLQ-C30和QLQ-PR25。
- 由于EORTC QLQ-C30为通用模块且不直接评估前列腺癌特异问题,应与QLQ-PR25模块联合使用。
研究设计与样本
- 系统综述,依据COSMIN方法学评估随机对照试验中用于局限性前列腺癌患者的PROM的心理测量学特性。
- 检索MEDLINE和Embase以识别评估PROM心理测量学特性的出版物,共纳入27项研究。
主要发现
- EPIC和EORTC QLQ-C30内部一致性高(Cronbach's α分别为0.46-0.96和0.68-0.94)但内容效度低。
- EORTC QLQ-PR25具有中等内容效度和内部一致性(Cronbach's α 0.39-0.87)。
- UCLA-PCI具有中等内容效度和高内部一致性(Cronbach's α 0.21-0.94),但不直接评估激素症状,而EORTC QLQ-PR25则评估。
关键数值与推荐
- EPIC的Cronbach's α为0.46-0.96,内容效度低。
- EORTC QLQ-C30的Cronbach's α为0.68-0.94,内容效度低。
- EORTC QLQ-PR25的Cronbach's α为0.39-0.87,内容效度中等。
- UCLA-PCI的Cronbach's α为0.21-0.94,内容效度中等。
临床怎么用
- 作者认为,EORTC QLQ-C30和QLQ-PR25是评估局限性前列腺癌患者PROM时测量学特性证据和可行性最佳的工具。
- 作者指出,EORTC QLQ-C30为通用模块,不直接评估前列腺癌特异问题,应与QLQ-PR25模块联合使用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prostate cancer (PCa) is the second most common cancer among men worldwide. Urinary, bowel, and sexual function, as well as hormonal symptoms and health-related quality of life (HRQoL), were prioritised by patients and professionals as part of a core outcome set for localised PCa regardless of treatment type. OBJECTIVE: To systematically review the measurement properties of patient-reported outcome measures (PROMs) used in localised PCa and recommend PROMs for use in routine practice and research settings. EVIDENCE ACQUISITION: The psychometric properties of PROMs measuring functional and HRQoL domains used in randomised controlled trials including patients with localised PCa were assessed according to the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) methodology. MEDLINE and Embase were searched to identify publications evaluating psychometric properties of the PROMs. The characteristics and methodological quality of the studies included were extracted, tabulated, and assessed according to the COSMIN criteria. EVIDENCE SYNTHESIS: Overall, 27 studies evaluating psychometric properties of the Expanded Prostate Cancer Index Composite (EPIC), University of California-Los Angeles Prostate Cancer Index (UCLA-PCI), European Organisation for Research and Treatment of Cancer (EORTC) quality of life core 30 (QLQ-C30) and prostate cancer 25 (QLQ-PR25) modules, International Index of Erectile Function (IIEF), and the 36-item (SF-36) and 12-item Short-Form health survey (SF-12) PROMs were identified and included in the systematic review. EPIC and EORTC QLQ-C30, a general module that assesses patients' physical, psychological, and social functions, were characterised by high internal consistency (Cronbach's α 0.46-0.96 and 0.68-0.94 respectively) but low content validity. EORTC QLQ-PR25, which is primarily designed to assess PCa-specific HRQoL, had moderate content validity and internal consistency (Cronbach's α 0.39-0.87). UCLA-PCI was characterised by moderate content validity and high internal consistency (Cronbach's α 0.21-0.94). However, it does not directly assess hormonal symptoms, whereas EORTC QLQ-PR25 does. CONCLUSION: The tools with the best evidence for psychometric properties and feasibility for use in routine practice and research settings to assess PROMs in patients with localised PCa were EORTC QLQ-C30 and QLQ-PR25. Since EORTC QLQ-C30 is a general module that does not directly assess PCa-specific issues, it should be adopted in conjunction with the QLQ-PR25 module. PATIENT SUMMARY: We reviewed and appraised the measurement properties of patient-reported outcome measure questionnaires used for patients with localised prostate cancer. We found good evidence to suggest that two questionnaires (EORTC QLQ-C30 and QLQ-PR25) can be used to measure urinary, bowel, and sexual functions and health-related quality of life.
引用
- Ratti MM, Gandaglia G, Alleva E, et al. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. Eur Urol Oncol. 2021. PMID: 34785188. doi:10.1016/j.euo.2021.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。